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Abstract
Introduction: The classification of breast cancer patients into risk groups provides a powerful tool for the identification of
patients who will benefit from aggressive systemic therapy. The analysis of microarray data has generated several gene
expression signatures that improve diagnosis and allow risk assessment. There is also evidence that cell proliferation-related
genes have a high predictive power within these signatures.
Methods: We thus constructed a gene expression signature (the DM signature) using the human orthologues of 108
Drosophila melanogaster genes required for either the maintenance of chromosome integrity (36 genes) or mitotic division
(72 genes).
Results: The DM signature has minimal overlap with the extant signatures and is highly predictive of survival in 5 large
breast cancer datasets. In addition, we show that the DM signature outperforms many widely used breast cancer signatures
in predictive power, and performs comparably to other proliferation-based signatures. For most genes of the DM signature,
an increased expression is negatively correlated with patient survival. The genes that provide the highest contribution to
the predictive power of the DM signature are those involved in cytokinesis.
Conclusion: This finding highlights cytokinesis as an important marker in breast cancer prognosis and as a possible target
for antimitotic therapies.
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Introduction
A reliable prediction of the outcome of a breast cancer is
extremely valuable information for deciding a therapeutic strategy.
The analysis of gene expression profiles obtained with microarrays
has allowed identification of gene sets, or genetic ‘‘signatures’’, that
are strongly predictive of poor prognosis (see [1,2] for a recent
survey). In the past few years, two types of cancer signatures have
been developed, commonly designated as ‘‘bottom-up’’ or ‘‘top-
down’’. In top-down (or supervised) signatures, the risk-predicting
genes are selected by correlating the tumor’s gene expression
profiles with the patients’ clinical outcome. One of the most
powerful top-down signatures is the so-called 70-gene signature,
which includes genes regulating cell cycle, invasion, metastasis and
angiogenesis [3]. This signature outperforms standard clinical and
histological criteria in predicting the likelihood of distant
metastases within five years [4]. Although highly predictive of
cancer outcome, top-down signatures have the drawback of
including different gene types, thereby preventing precise
definition of the biological processes altered in the tumor.
Bottom-up (or unsupervised) signatures are developed using sets
of genes thought to be involved in specific cancer-related processes
and do not rely on patients’ gene expression data. Examples of
these signatures are the ‘‘Wound signature’’ that includes genes
expressed in fibroblasts after serum addition with a pattern
reminiscent of the wound healing process [5,6], the ‘‘Hypoxia
signatures’’ that contains genes involved in the transcriptional
response to hypoxia [7-9], and the ‘‘Proliferation signatures’’ that
include genes expressed in actively proliferating cells [10,11].
Other bottom-up signatures are the ‘‘Embryonic Stem cells (ES)
signature’’ [12], the proliferation, immune response and RNA
splicing modules signature [13] (henceforth abbreviated as
‘‘Module signature’’) the ‘‘invasiveness gene signature’’ (IGS) [14]
and the chromosomal instability signature (CIN) [15]. The ‘‘ES
signature’’ is based on the assumption that cells with tumor-
initiating capability derive from normal stem cells. This signature
reflects the gene expression pattern of embryonic stem cells (ES)
and includes genes that are preferentially expressed or repressed in
this type of cells [12]. The ‘‘Module signature’’ was generated by
selecting gene sets that were enriched in nine pre-existing
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processes including the immune response, cell proliferation, RNA
splicing, focal adhesion, and apoptosis [13]. The IGS signature
includes genes that are differentially expressed in tumorigenic
breast cancer cells compared to normal breast-epithelium cells; the
186 genes of this signature are involved in a large variety of
cellular functions and processes [14]. The CIN signature has
features of both top-down and bottom-up signatures; it was
developed by selecting genes with variations in the expression level
correlated with the overall chromosomal aneuploidy of tumor
samples [15].
Tumors are characterized by frequent mitotic divisions and
chromosome instability. In addition, several independent studies
have shown that mitotic activity in breast cancer samples from
lymph node-negative patients positively correlates with poor
prognosis [16-19]. We thus reasoned that genes required for
mitotic cell division and genes involved in the maintenance of
chromosome integrity could be used to develop a new cancer
signature. In a recent RNAi-based screen performed in Drosophila
S2 cells [20], we identified 44 genes required to prevent
spontaneous chromosome breakage and 98 genes that control
mitotic division. Thus, considering the strong phylogenetic con-
servation of the mitotic process, rather than relying on functional
annotation databases, we used the 142 Drosophila genes identified
in the screen [20] to develop a new bottom-up signature that
includes genes involved in cell division but not yet annotated in the
literature. 108 of these 142 Drosophila genes have unambiguous
human orthologs. Here we show that these 108 human genes
constitute an excellent signature to predict breast cancer outcome.
This Drosophila mitotic signature, or ‘‘DM signature’’, has minimal
overlap with pre-existing gene signatures and outperforms most of
them in predictive power.
Materials and Methods
Definition of the DM signature
The 142 D. melanogaster mitotic genes described in [20] were first
converted into Entrez gene ids (file gene_info.gz downloaded from
the Entrez Gene ftp site in June 2008). We then used Homologene,
build 62, to obtain the 108 human orthologues that compose the
DM signature. We considered only one-to-one orthology relation-
ships reported in Homologene. This criterion led to the exclusion
from the DM signature of several human genes that are commonly
considered homologous to the Drosophila genes. However, the
degree of homology between these human genes and their
Drosophila counterparts was not sufficient for inclusion in Homo-
logene.
Breast cancer datasets
We used the following publicly available breast cancer datasets:
NKI [4]; Pawitan ([21] - Gene Expression Omnibus (GEO-) series
GSE1456); Miller ([22] - GEO series GSE3494); Sotiriou ([23] -
GEO series GSE2990); Desmedt ([24] - GEO series GSE7390);
and Wang ([25] - GEO series GSE2034). We used relapse-free
survival times when available, and overall survival times otherwise.
Since the Sotiriou, Desmedt and Miller datasets have some
patients in common, we merged the Sotiriou and Desmedt
datasets in a single dataset, from which we removed the patients
included in the Miller dataset. We refer to this combined dataset as
the Sotiriou-Desmedt dataset. Normalized expression data and
clinical data for the NKI dataset were obtained from http://www.
rii.com/publications/2002/nejm.html. For the Affymetrix-based
datasets, we obtained gene expression values from the raw data,
using MAS 5.0 algorithm as implemented in the Simpleaffy [26]
package of Bioconductor [27]. For all datasets we considered only
the probesets unambiguously assigned to one Entrez Gene ID in
the platform annotation. For the Affymetrix platform, we used the
annotation provided by the manufacturer, version 25, which
allowed us to identify single or multiple probesets for 105 of the
108 DM signature genes. For the NKI dataset we used the
annotation file provided in the website mentioned above; the
correspondence between sequence accession number and Entrez
gene was obtained from the Entrez gene ftp site; 98 of the 108 DM
genes were thus associated with one or multiple probes.
Determination of the predictive power of the genes in
the DM signatures by clustering analysis
To determine whether the expression profiles of the genes
included in the DM signature are significantly and robustly
correlated with the disease outcome we used the following
procedure on the datasets mentioned above: (a) selecting the
microarray probes unambiguously associated to the signature
genes; (b) creating two groups of patients by Pearson correlation-
based hierarchical clustering, using only the expression profiles of
the probes selected in step a; (c) determining by a standard log-
rank test, as implemented in the survival library of R, whether the
cumulative probability of survival is significantly different between
the two groups.
Determination of prognostic scores
For all datasets we divided the patients into two groups (good- and
poor-outcome) based on their status at fiveyears. We then calculated
the prognostic scores for outcome prediction at five years using the
following procedures. For the 70-gene signature, the score of a
patient is the cosine-correlation of the expression profile of genes
with good-prognosis found in http://www.rii.com/publications/
2002/nejm.html [4]. The genes in the signature, given at as acces-
sion numbers, were translated into Entrez gene IDs and then into
Affymetrix probesets using Affymetrix annotation files, version 25.
We obtained 76 probesets for the HG-U133A platform, and 109
probesets for the HG-U133A and HG-U133B platforms considered
together. Probesets corresponding to the same gene were assigned
the same coefficient in the good-prognosis profile.
For the Wound and IGS signatures, the score of a patient is
given by the Pearson correlation of the expression profile of the
signature genes. For the Wound signature the core serum response
centroid is available at http://microarray-pubs.stanford.edu/
wound [5]. The genes in the signature were translated into Entrez
gene ids and then into Affymetrix probesets using the procedure
described above. We obtained 493 probesets for the HG-U133A
platform, and 667 probesets for the HG-U133A and HG-U133B
platforms considered together. Probesets corresponding to the
same gene were assigned the same expression value in the core
serum response centroid. The centroid for the IGS signature is
directly given in Affymetrix probesets [14].
For the CIN [15], Proliferation [11] and Hypoxia [9]
signatures, the score of a patient is the sum of the logarithmic
expression of the signature genes in the patient sample. For the
CIN and Proliferation signatures, the gene symbols, were
translated first into Entrez gene ids and then into Affymetrix
probesets as described above. The Hypoxia signature is directly
given in terms of Affymetrix probesets.
For the DM signature, the prognostic score of a patient is given
by
X
g
z(g)x(g,p)
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z(g) is the z-score of probeset g computed in the Pawitan dataset
and x(g,p) is the logarithmic expression level of probeset g in patient
p. The Affymetrix probesets that comprise the DM signature
together with their z-scores are reported in Table S1.
We used Receiver Operating Characteristic ROC curves to
compare the scalable scores on three datasets (Miller, Wang and
Sotiriou-Desmedet). The area under the curves and the related
standard error were computed using the Hmisc library and
programs available at http://biostat.mc.vanderbilt.edu/s/Hmisc.
The Pawitan and NKI datasets were not used in this comparison
because they were involved in the training of the DM and 70-gene
signatures, respectively.
Contribution of specific gene classes to the predictive
power of the signature
The contribution of each probeset g to the difference in score
between poor- and good-prognosis patients is defined as
P(g){G(g) ðÞ z(g)
where P(g) (G(g)) is the logarithmic expression of the probeset
averaged on all poor (good) prognosis patients and z(g) is the z-
score of the probeset. Given a subset of the DM signature (e.g.
cytokinesis-related genes), we used a Mann-Whitney U test to
compare the contribution of the probesets included in the subset to
the contribution of all the other probesets.
Results
Generation of the DM signature
We have recently carried out an RNAi-based screen to detect
Drosophila genes required for chromosome integrity and for the
fidelity of mitotic division [20]. Since these types of genes tend to
be transcriptionally co-expressed, we first used a co-expression-
based bioinformatic procedure to select a group of 1,000 genes
highly enriched in mitotic functions. We then performed RNAi
against each of these genes in Drosophila S2 cultured cells.
Phenotypic analysis of dsRNA-treated cells allowed the identifica-
tion of 142 genes representative of the entire spectrum of functions
required for proper transmission of genetic information. 44 of
these genes were required to prevent spontaneous chromosome
breakage. The remaining 98 genes specified a variety of mitotic
functions including those required for spindle assembly, chromo-
some segregation and cytokinesis [20]. Based on the observed
RNAi phenotypes, these 142 genes were subdivided into 18
phenoclusters [20].
To construct the DM signature we identified the human
homologues of these Drosophila genes, according to Homologene
[28]. Both the genes required for chromosome integrity and those
involved in the mitotic process turned out to be highly conserved
in humans. 36 of the 44 chromosome-integrity genes and 72 of the
98 mitotic genes had clear human orthologues. These 108 human
genes, and their classification according to the phenotypes
associated with RNAi-mediated silencing of their Drosophila
counterparts, are listed in Tables 1 and S1. Collectively, the
genes in Table 1 constitute the DM signature. The remaining 34
Drosophila genes identified in the screen [20] were not included in
the DM signature because they did not have an unambiguous
human homologue in Homologene (Release 62).
The DM signature shares very few genes with pre existing
signatures. We considered the top- down 70-gene signature [3]
and several bottom-up signatures based on various aspects of
cancer biology: the Wound signature [5,6]; the ES signature [12];
the IGS signature [14] the Hypoxia signatures of Sung et al. [8]
and Winter et al. [9]; the Proliferation signature of Starmans et al.
[11]; the proliferation/immune response/RNA splicing (Module)
signature[13]andthechromosomalinstability(CIN)signature[15].
The number of genes that the DM signature shares with the 70-
gene, ES, IGS, Wound and Hypoxia signatures is extremely small.
The overlap is higher with the Module, Proliferation and CIN
signatures, but none of these signatures shares more than 20% of its
genes with the DM signature (Table 2).
25 of the 108 genes of the DM signature are included in the list
of genes periodically expressed during the cell cycle in HeLa cells
[10], compared to 5.8 expected by chance (P=2.2E-10). Thus, as
expected for genes involved in cell division, a substantial fraction
of the DM signature genes has a cell cycle-dependent expression.
The prognostic value of the DM signature
For a preliminary assessment of the predictive power and
robustness of the DM signature we used six publicly available
breast cancer datasets: (i) NKI, which contains expression data
from primary breast tumors of 295 consecutive, relatively young
(age,52 yrs) patients [4]; (ii) Pawitan, which includes data from
159 consecutive breast cancer patients [21]; (iii) Miller, with data
from 251 patients selected from a consecutive series based on the
quality of the material [22]; (iv) Desmedt and (v) Wang, which
contains expression data from 198 and 286 lymph-node negative,
systemically untreated patients, respectively [24,25]; (vi) Sotiriou,
which includes 189 invasive breast carcinomas [23]. Due to the
presence of common samples, we merged the Desmedt and
Sotiriou datasets into a single one and removed from it the patients
that were also included in the Miller dataset. All datasets contain
both ER-positive and ER-negative samples.
Although most of these gene expression data were generated
using the same microarray platform, and could in principle be
merged in a single dataset as recently described [13], we evaluated
the DM signature on the individual datasets. We chose this
approach because the robustness of a gene signature on
independent datasets is an important criterion for validation of
its predictive power. In our prognostic power analysis, we used
relapse-free survival times when available, or overall survival times
otherwise. Because three genes of the DM signature (H3F3A,
PPAN-P2RY11 and KIF4) were not represented in the Affymetrix
platform, we performed our analyses on 105 genes. For each
dataset, patients were divided into two groups based on the
expression profiles of the genes in the DM signature using
hierarchical clustering. Differences in survival probability between
the two groups were then evaluated with a standard log-rank test
on Kaplan-Meier curves. Figure 1 shows that the differences in
survival are statistically significant for all datasets considered.
As mentioned above, the DM signature contains two broad
classes of genes, namely 72 mitotic genes (71 in platform) and 36
genes required for the maintenance of chromosome integrity (34 in
platform). To determine the relative contribution of these two gene
classes to the predictive power of the DM signature, we performed
the analysis using the two categories of genes separately. Both gene
groups turned out to be independently predictive of survival
(Figure S1). However the predictive power of the global signature
was higher in all cases.
We also asked whether the DM signature is predictive of
survival in other tumors besides breast cancer. Using the
hierarchical clustering approach described above, we found that
the DM signature is predictive of survival in a large lung cancer
dataset [29] (P=3e26) and in a glioma dataset [30] (P=0.0170).
However, the DM signature is not significantly predictive in other
lung cancer [31] and glioma [32] datasets, and in renal [33] or
Drosophila Mitotic Signature
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non-breast datasets are reported in Table S2.
Evaluation of a prognostic score for the DM signature
Subdivision of patients into risk groups using the unsupervised
clustering-based approach described above allows assessment of
the predictive power of a gene signature, but does not allow
specificity (fraction of low-risk patients correctly classified) and
sensitivity (fraction of high-risk patients correctly classified) to be
tuned according to specific requirements. However, such tuning is
important in clinical applications, because the misclassification of a
high-risk patient is potentially more harmful than the misclassi-
fication of a low-risk patient. Indeed, the 70-gene signature [3],
which is used in clinical practice, assigns a risk score to each
patient; patients are then classified based on a score threshold that
can be tuned to obtain the desired compromise between specificity
and sensitivity. Scalable prognostic scores, each computed from
gene expression data with a specific algorithm, have been
previously defined also for the Wound [6], IGS [14], Proliferation
[11], CIN [15] and Hypoxia [9] signatures.
We determined a scalable prognostic score for the DM
signature, using a procedure similar to that employed by Wang
and co-workers [25]. We define the DM prognostic score as the
sum of the logarithmic expression values of the signature genes,
each multiplied by its z-score. The Cox z-score measures the
correlation between the expression pattern of a gene and survival
of the patient. A positive (negative) z-score indicates negative
(positive) correlation between the gene expression level and
patient’s survival time.
We used the Pawitan dataset as training set and computed the
Cox z-scores for the Affymetrix probesets associated with the DM
signature (the z-scores of all probesets are shown in Table S1). The
distribution of these z-scores is consistently shifted towards positive
values compared to the distribution of the z-scores of all genes
represented on the microarrays (P-values between 1.1e-6 and 3.3e-
15 from one-sided Mann-Whitney U test) (Figure S2). Thus, as
expected for proliferation-related genes, for most genes in the DM
signature an increased expression level is negatively correlated
with survival.
We then compared the DM signature score with the scores of 6
other scalable signatures for performance in predicting cancer
outcome at 5 years. For this analysis we used ROC curves
generated with the Affymetrix datasets not employed for training
(Miller, Sotiriou-Desmedt and Wang). The scores of the CIN [15],
Proliferation [11], 70-gene [3], Wound [6], IGS [14], and
Hypoxia [9] signatures were computed as described in the
respective references, after mapping the genes to the Affymetrix
platform (see Methods for details). As shown in Figure 2, the
predictive power of the 3 proliferation-based signatures (DM, CIN
and Proliferation), measured by the Area Under ROC Curves
(AUC), is very similar in all datasets and systematically higher than
that of the 70-gene, Wound, IGS, or Hypoxia signature.
Table 2. The DM signature shares very few genes with other
major cancer signatures.
Signature
# of genes in
the signature
Genes in common with
the DM signature
Module 261 18 (6.9%)
CIN 71 14 (19.7)
ES 1029 14 (1.4%)
Wound 371 6 (1.6%)
Proliferation 52 6 (11.5%)
70-gene 61 2 (3.3%)
Hypoxia (Winter) 92 2 (2.2%)
IGS 175 2 (1,1%)
Hypoxia (Sung) 126 1 (0.8%)
doi:10.1371/journal.pone.0014737.t002
Table 1. Classification of the 108 genes of the DM signature according to the RNAi phenotypes of their Drosophila orthologues.
The phenoclusters, indicated in bold characters, are described in detail in [20].
RNAi phenotypes elicited by the Drosophila genes Names of the human orthologues
Chromosome aberrations (CA) C15orf44, CASP7, CNOT3, CTPS, CUL4B, CWC15, DCAKD, DDB1, FRG1, H3F3A,
MSH6, ORC5L, PCNA, PIAS1, PPAN-P2RY11, POLA1, PRIM2, PRPF3, RAD54L, RFC2,
RPA1, RRM2, SART1, SF3A3, SMC1A, TAF6, TFDP2, TK2, TPR, TYMS, WBP11, WDR46,
WDR75, XAB2, XRN2, ZMYM4.
Abnormal chromosome structure. CC1, loss of sister chromatid cohesion
in heterochromatin; CC2 and CC3, defective lateral and longitudinal
chromosome condensation, respectively
CC1: MCM3, MCM7, SMC3.
CC2: NCAPD2, NCAPG, SMC4, SMC2.
CC3: MASTL, ORC2L, TOP2A.
Abnormal chromosome segregation. CS1, defective chromosome
duplication; CS2, precocious sister chromatid separation; CS3 and CS4,
lack of sister chromatid separation; CS5, defective chromosome
segregation during anaphase
CS1: CDT1.
CS2: BUB3, KNTC1, ZW10.
CS3 and CS4: ASCC3L1, CCNB1, CDC40, DHX8, KIAA1310, LSM2, PRPF31, SF3A1,
SF3A2, SF3B1, SF3B2, SF3B14, SLU7, SNRPA1, SNRPE, TXNL4A, U2AF1, U2AF2.
CS5: ANAPC5, ANAPC10, CDC20, KIF4A, KIN, PSMC1, SFRS15.
Abnormal spindle morphology: SA1, short spindles; SA2, spindles
with a low MT density; SA3, poorly focused spindle poles, SA4
miscellaneous spindle defects
SA1: CKAP5, EIF3A, EIF3D, EIF3E, EIF3I, GTF3C3, MAPRE3, NOC3L, RRP1B, TBK1,
THOC2, TUBB2C, WDR82.
SA2: TRRAP, TUBGCP4, TUBG2.
SA3: ASPM, CENPJ, MKI67IP, PPP1R8.
SA4: CDC2, KIFC1, KIF11, KIF18A.
Abnormal spindle and chromosome structure: SC1, defective
chromosome condensation and cytokinesis; SC2, multiple mitotic defects
SC1: AURKC, RBBP7.
SC2: PLK1.
Frequent cytokinesis failures: CY1 and CY2, defective in early and late
cytokinesis, respectively
CY1: ECT2, KIF23, PRC1, RACGAP1.
CY2: ANLN, CIT.
doi:10.1371/journal.pone.0014737.t001
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signatures perform similarly in predicting outcome at 5 years (see
Fig. 2), we compared their performance in greater detail at three
sensitivity values. In Table 3, we show for each signature and
dataset both the specificity and the P-value of the log-rank test
that compares the survival probabilities of the two groups of
patients identified by the signature. These parameters provide
different assessments of the predictive power: while the specificity
refers to the ability of the signature to predict the outcome only at
the 5-year endpoint, the P-value takes into account the complete
survival curves, and thus measures the ability to stratify the
patients over the whole time range. The results in Table 3 show
that the DM signature performs slightly better than the other two
signatures at the higher sensitivities, especially in terms of P-
value. The differences in performance between the three
signatures are driven by the fraction of patients that are
discordantly classified in the different signatures. These fractions,
which range from ,2% to ,10% in the three datasets, are
reported in Table S3.
We also performed multivariate Cox analysis to ascertain
whether the DM signature predicts survival independently of other
molecular and clinical tumor markers. The results for the Miller
dataset (Table 4), which is the richest in clinical annotations, and
those for the other datasets (Table S4) clearly show that the DM
score is a predictor independent of several tumor parameters.
Multivariate Cox analysis on the Miller dataset showed that also
the other proliferation-based signatures are independent of the
same parameters considered for the DM signature (Table S5).
The patients that would benefit the most from an effective
prognostic predictor are those with lymph-node negative breast
cancers. The Wang dataset includes only lymph-node negative
patients, while the Miller and Sotiriou-Desmedt datasets include
both node-positive and negative patients. Therefore we evaluated
the performance of the DM signature on the patients of the latter
datasets by computing the AUC under ROC curves at the five-
year endpoint. For both the Miller and the Sotiriou-Desmedt
studies, the AUC values obtained for the lymph node-negative
patients were very similar to the values obtained for the entire
Figure 1. Predictive power of the DM signature. Kaplan-Meier analysis using the DM signature shows significant differences in survival of
patients from five independents breast cancer datasets.
doi:10.1371/journal.pone.0014737.g001
Figure 2. Comparative evaluation of the prognostic score of the DM signature. The prognostic score of the DM signature is compared to
those obtained from the CIN [15], Proliferation [11], IGS [14], Hypoxia [9], 70-gene [3], and Wound [5] signatures in the three datasets not used for
training. The scores are used to predict outcome at five years. The bars show the areas under the ROC curves (AUC).
doi:10.1371/journal.pone.0014737.g002
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conclude that the DM signature is a robust predictor of survival in
lymph-node negative patients.
Contribution of specific genes and gene classes to the
predictive power of the DM signature
We next asked whether any of the phenotypic classes identified
by the RNAi screen (chromosome condensation, chromosome
integrity, chromosome segregation, spindle assembly and cytoki-
nesis) [20] is especially relevant in separating poor- from good-
prognosis patients. We computed the contribution of each
probeset in the DM signature to the difference in score between
poor- and good-outcome patients (see Methods); we then
compared the contribution of specific gene classes to the total
score of the 105 genes of the DM signature. For the three
Affymetrix datasets not used as training, the cytokinesis genes
(ANLN, CIT, ECT2, KIF23, PRC1, RACGAP1) turned out to
contribute to the difference in score significantly more than other
genes (P-values between 0.0025 and 0.012, two-sided Mann-
Whitney U test). The function of these genes is highly conserved,
as they are required for cytokinesis in both Drosophila and humans
(reviewed in [34]). Interestingly, high z-scores were also observed
for ASPM, KIF18A and PLK1 (Table S1). The Drosophila homo-
logues of these genes (asp, Klp67 and polo) are involved in multiple
mitotic stages and are required for cytokinesis [34]. In addition
there is evidence that ASPM and PLK1 are involved in human cell
cytokinesis [34]. Thus, it appears that cytokinesis genes have
higher prognostic value than other mitotic genes and genes
required for chromosome integrity.
In the DM signature, there are a few genes whose expression is
positively correlated with survival (Table S1). The gene with the
most negative z-score is PIAS1 (z=24.07, averaged on two
probesets), an E3 ligase involved in sumoylation of DNA repair
proteins including BRCA1 [35]. Remarkably, it has been recently
shown that the expression of this gene is substantially reduced in
colon cancers [36].
Discussion
We have shown that the DM signature is highly predictive of
survival in five major breast cancer datasets. The DM signature
contains two classes of genes required for cell proliferation: genes
that maintain the integrity of mitotic chromosomes and genes that
mediate mitotic division. Cell proliferation-associated genes have
been previously used to construct several cancer signatures, and
large subsets of this type of genes are included in most supervised
signatures [37]. Thus, it has been suggested that genes required for
cell proliferation may underlie the prognostic power of many
cancer signatures [37].
Consistent with this idea, we found that the DM signature has a
predictive power for breast cancer outcome similar to that of two
other proliferation-based signatures, the CIN signature [15] and
the Proliferation signature of Starmans et al. [11]. In addition, we
showed that the DM signature outperforms 4 additional signatures
that contain different proportions of proliferation-related genes,
the Hypoxia [9] the Wound [5,6], the IGS [14] and 70-gene
signature, which is currently used in clinical practice [3].
Table 3. Comparison of the performances of the proliferation-based signatures.
90% sensitivity DM CIN Proliferation
P value Specificity P value Specificity P value Specificity
Miller 2.26E-04 0.318 5.44E-04 0.352 4.89E-04 0.352
Sotiriou-Desmedt 4.44E-03 0.335 0.0312 0.329 0.0124 0.329
Wang 4.08E-03 0.226 0.0114 0.260 0.015 0.227
70% sensitivity DM CIN Proliferation
P value Specificity P value Specificity P value Specificity
Miller 1.77E-04 0.614 7.63E-03 0.523 3.02E-03 0.562
Sotiriou-Desmedt 4.51E-04 0.613 4.25E-04 0.600 1.24E-03 0.574
Wang 4.25E-04 0.547 5.58E-04 0.547 1.19E-03 0.536
50% sensitivity DM CIN Proliferation
P value Specificity P value Specificity P value Specificity
Miller 3.91E-04 0.733 8.81E-04 0.705 1.42E-03 0.716
Sotiriou-Desmedt 0.138 0.697 0.134 0.722 0.161 0.690
Wang 6.85E-03 0.669 2.41E-03 0.691 0.022 0.641
The best performing signature in terms of specificity or P-value is shown in bold.
doi:10.1371/journal.pone.0014737.t003
Table 4. Multivariate Cox analysis for the Miller dataset
shows that the DM score is predictive of survival
independently of other molecular and clinical tumor markers.
Covariate Odd ratio (95% C.I.) P-value
LN (positive=1, negative=0) 2.82 (1.53–5.21) 8.95E-04
DM score (range 0–10) 1.32 (1.08–1.60) 0.0057
Size (mm) 1.04 (1.01–1.06) 0.0065
ER (positive=1, negative=0) 3.34 (1.11–10.00) 0.031
Age (years) 1.02 (1.00–1.04) 0.057
PGR (positive=1, negative=0) 0.53 (0.23–1.23) 0.14
P53 (mutant=1, wt=0) 0.97 (0.49–1.95) 0.95
Grade (1–3) 0.99 (0.56–1.75) 0.96
LN=lymph node status; ER=estrogen receptor status; PGR=progesteron
receptor status.
doi:10.1371/journal.pone.0014737.t004
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proliferation genes are the most powerful predictors of breast
cancer outcome.
What isthebasisofthehighprognosticvalue oftheDMsignature
and why does it outperform many of the extant signatures? We
propose that the high performance of the DM signature reflects its
specifically high content in genes truly involved in cell proliferation.
The proliferation-associated genes in other signatures have been
selected on the basis of their periodic expression pattern during the
cell cycle and include several genes that, although periodically
expressed, are not involved in basic cell cycle processes [10,37]. In
contrast, genes predicted to play a conserved role in either the
maintenance of chromosome integrity or mitosis, are expected to be
essential for cell cycle progression and cell proliferation. The
expression of these genes should therefore reflect the cell
proliferation rate within a cancer better than the gene sets of the
other signatures. Consistent with this idea, we have shown that most
of the DM signature genes with a high predictive power display
increased expression in poor outcome patients (Figure S2).
The idea that survival of breast cancer patients is negatively
correlated with the frequency of dividing cells within a tumor
sample is not novel. Indeed, it has been shown that a correct
measure of the mitotic activity [16,19] can accurately identify
high-risk cases among lymph node-negative patients. However, to
be effective, the analysis of mitotic activity must be carried out by
well-trained personnel, using a strictly defined protocol [16,19].
On the other hand, measuring gene expression in tumor biopsies,
might not take into account intra-tumor heterogeneity [16],
although it might be technically less demanding. We do not know
how prognostic values obtained by cytological analysis of mitotic
activity compare with values obtained with the DM signature or
with the other proliferation signatures. Unfortunately, in the
available studies where both mitotic activity and gene expression
have been determined in the same tumor sample [4,11], the
mitotic activity was not measured by protocols of proved reliability
[38], preventing a direct comparison. We believe that future
studies addressing this point will be instrumental to refine our tools
for risk assessment in lymph node-negative patients.
We have shown that a group of genes required for cytokinesis
(ANLN, CIT, ECT2, KIF23, PRC1, RACGAP1, ASPM, KIF18A and
PLK1) contributes to the predictive power of the DM signature
significantly more than the other genes. All cytokinesis genes
display high positive z-scores, indicating that their increased
expression is negatively correlated with survival. Strikingly, there is
evidence that ANLN, ECT2, PRC1, RACGAP1, ASPM, and PLK1
are upregulated in a variety of human cancers and that their
overexpression often correlates with poor outcome (see for
example [39-47] and references therein). In addition, it has been
shown that two of these genes, ETC2 and ANLN, are amplified in
cancer cells [42,48]. These findings raise the question of why
cytokinesis genes have a higher prognostic value and tend to be
more upregulated poor prognosis patients compared to other
mitotic genes. It is possible that overexpression of cytokinesis genes
is an oncogenic factor per se. However, the finding that PRC1
overexpression does not result in cell growth enhancement [45]
argues against this possibility. Another possibility is that cytokinesis
proteins are limited in amount or stability compared to other
mitotic proteins. That is, when cell proliferation is strongly
enhanced, normal levels of gene transcription and translation
would not be sufficient to produce the amounts of cytokinesis
proteins required for proper execution of the process. As a result,
cancers cell clones overexpressing cytokinesis genes would be
favoured over clones in which these genes are normally expressed.
This hypothesis is very attractive but it is not sufficiently supported by
current data. Further experiments will be required to examine the
role of cytokinesis genes in cancer development. For example, one
could produce stably transformed cancer-derived cells and ask
whether overexpression of cytokinesis genes confers growth advan-
tage compared to overexpression of other types of mitotic genes.
Our study indicates that the DM signature improves risk
stratification for breast cancer patients compared to the major
extant signatures. In addition, the identification of new cancer
prognostic genes with well-defined biological functions, such as
those of the DM signature, provides valuable information for
development of new prognostic tools based on gene expression.
For example, according to a previous approach [6,11,13] the
genes of the DM signature could be merged with those of other
signatures to further improve risk stratification. Finally, our finding
that cytokinesis genes tend to be overexpressed in patients with
poor prognosis sets forth this class of genes and their protein
products as targets for antimitotic therapies.
Supporting Information
Figure S1. Predictive power of the mitotic and chromosome-
integrity genes of the DM signature. Kaplan-Meier survival
analysis was performed on five breast cancer datasets using either
the 34 chromosome integrity genes or the 71 mitotic genes of the
DM signature represented in the Affymetrix platform.
Found at: doi:10.1371/journal.pone.0014737.s001 (0.07 MB
PDF)
Figure S2. Distribution of the z-scores of the genes of the DM
signature compared to the distribution of z-scores of all genes
represented in five breast cancer datasets. Distribution of the z-
scores of the genes of the DM signature compared to the
distribution of z-scores of all genes represented in five breast
cancer datasets. The z-scores were obtained using Cox univariate
analysis. Note that the distribution of the signature genes is shifted
towards positive values.
Found at: doi:10.1371/journal.pone.0014737.s002 (0.28 MB
PDF)
Table S1. Ranking of the Affymetrix probesets of the DM
signature according to their z-scores. The Affymetrix probesets
associated with the DM signature genes are ranked according to
their Cox z-score computed on the training dataset (Pawitan). The
contribution to the difference in score between poor and good
prognosis patients in the other datesets is also reported. The
phenoclusters associated with the Drosophila genes [20] are
abbreviated as follows: CA, chromosome aberrations; CC1, loss of
sister chromatid cohesion in heterochromatin; CC2 aberrant
lateral chromosome condensation; CC3, aberrant longitudinal
chromosome condensation; CS1, defective chromosome duplica-
tion; CS2, precocious sister chromatid separation; CS3 and CS4,
lack of sister chromatid separation; CS5, defective chromosome
segregation during anaphase; SA1, short spindles; SA2, spindles
with a low MT density; SA3, poorly focused spindle poles; SA4
miscellaneous spindle defects; SC1, defective chromosome con-
densation and cytokinesis; SC2, multiple mitotic defects; SC1,
defective in early cytokinesis; SC2, defective in late cytokinesis.
Found at: doi:10.1371/journal.pone.0014737.s003 (0.06 MB
XLS)
Table S2. Predictive power of the DM signature in cancers
other than breast. The P-values were obtained from the log-rank
test by comparing the cumulative probability of survival of clusters
of patients in other cancer types.
Found at: doi:10.1371/journal.pone.0014737.s004 (0.01 MB
XLS)
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tion-based signatures. For each dataset and pair of proliferation-
based signatures, we report the number of patients classified in
different outcome groups, using score cutoffs corresponding to the
same sensitivity.
Found at: doi:10.1371/journal.pone.0014737.s005 (0.01 MB
XLS)
Table S4. Cox multivariate analysis for the NKI, Sotiriou-
Desmedt and Wang datasets. The analysis shows that the DM
signature is a predictor independent of several clinical parameters.
Found at: doi:10.1371/journal.pone.0014737.s006 (0.01 MB
XLS)
Table S5. Cox multivariate analysis for the Miller dataset. The
analysis shows that the CIN and Proliferation signatures are
predictors independent of several clinical and molecular param-
eters.
Found at: doi:10.1371/journal.pone.0014737.s007 (0.01 MB
XLS)
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